advanced search

INJECTION

A FIVE-STEP APPROACH TO INNOVATION IN DRUG DELIVERY SYSTEMS
INDUSTRIALISATION
Michael Wiglenda
Gerresheimer
A FIVE-STEP APPROACH TO INNOVATION IN DRUG DELIVERY SYSTEMS
Michael Wiglenda explains Gerresheimer’s industrialisation offering and the five-step Gate-Model that guides its innovation process.
AUTOMATING PREVIOUSLY IMPOSSIBLE MANUAL INSPECTIONS USING MACHINE LEARNING & CONCURRENT VALIDATION
INDUSTRIALISATION
Steve Wardell
AUTOMATING PREVIOUSLY IMPOSSIBLE MANUAL INSPECTIONS USING MACHINE LEARNING & CONCURRENT VALIDATION
Steve Wardell and Catherine Thacker explore how machine learning technology is enabling the automation of challenging, or previously impossible, manual inspections.
CUSTOMISED INFUSION PUMPS: THE FUTURE OF SELF-ADMINISTRATION?
EXPERT VIEW
Shaul Eitan
CUSTOMISED INFUSION PUMPS: THE FUTURE OF SELF-ADMINISTRATION?
Shaul Eitan explores the challenges of home infusion and examines how customisation and connectivity could help provide a solution.
I SPY WITH MY LITTLE EYE: EYE TRACKING DRIVES PATIENT-CENTRED DEVELOPMENT OF CONNECTED SYSTEMS
CONNECTIVITY
Dr Andreas Schneider
Ypsomed
I SPY WITH MY LITTLE EYE: EYE TRACKING DRIVES PATIENT-CENTRED DEVELOPMENT OF CONNECTED SYSTEMS
The development of connected self-injection systems is driving industry to rethink its current approaches to patient-centred new product development. Andreas Schneider summarises a recent field study that used eye tracking for the formative usability testing of SmartPilot for YpsoMate.
MACRO TRENDS ACCELERATING THE ADOPTION OF CONNECTIVITY IN DRUG DELIVERY
CONNECTIVITY
Dr Ramin Rafiei
SHL Medical
MACRO TRENDS ACCELERATING THE ADOPTION OF CONNECTIVITY IN DRUG DELIVERY
Ramin Rafiei argues that connected therapeutics – the augmentation of drugs through sensors and connectivity – are now a clinical source for real-world data and provide an opportunity to bridge the efficacy-to-effectiveness gap. This next frontier in drug delivery, powered by connected therapeutics, will be data-driven, personalised, outcomes-based and accessible.
COMPLETING ITS TRANSITION FROM GENESIS TO MATURITY, BIOCORP OPENS NEW HORIZONS
CONNECTIVITY
Eric Dessertenne
Biocorp
COMPLETING ITS TRANSITION FROM GENESIS TO MATURITY, BIOCORP OPENS NEW HORIZONS
As Biocorp prepares for the market launch of its connected injector pen add-on, Mallya, Eric Dessertenne and Arnaud Guillet share insights about key steps in the company’s development. The article discusses the many partnership Biocorp has entered in to, and includes a mini-interview with Sergio Monti, Plant Manager for one such partner, V.A.R.I.
CONNECTED DEVICES – MEDICATION DELIVERY JUST GOT PERSONAL
CONNECTIVITY
Thierry Decock
Nemera
CONNECTED DEVICES – MEDICATION DELIVERY JUST GOT PERSONAL
Thierry Decock and Hadrien Gremillet explore how the obstacles to the adoption of connectivity can be overcome and how connected devices can deliver truly patient-centric care that will clearly improve adherence rates, whilst demonstrating a clear cost benefit to the pharmaceutical partner.
MIRCEA DESPA & DOUG McCLURE, BD
INTERVIEW
Dr Mircea Despa
BD (Becton Dickinson & Company)
MIRCEA DESPA & DOUG McCLURE, BD
In this interview, Dr Despa and Mr McClure discuss BD’s approach to connecting devices in its portfolio to meet patient, pharma and other stakeholder requirements. Their discussion focuses in particular on safety and security, highlighting the connected wearable injector, BD Libertas™ with Smart Option, as an example.
DON’T DEVELOP A CONNECTED DRUG DELIVERY DEVICE WITHOUT READING THIS
CONNECTIVITY
Matt Jones
DCA
DON’T DEVELOP A CONNECTED DRUG DELIVERY DEVICE WITHOUT READING THIS
Matt Jones summarises some of the key challenges and opportunities in the development of connected drug delivery devices, focusing in detail on deciding what a connected drug delivery device should do, designing for a coin cell, direct cellular connection and antenna design.
USER-CENTRED DEVICE CONNECTIVITY
EXPERT VIEW
Mark Tunkel
USER-CENTRED DEVICE CONNECTIVITY
Mark Tunkel and Carolyn Rose discuss the benefits of taking a user-needs approach, and mapping the patient journey, in a connectivity strategy.
LOW-COST CONNECTIVITY MEETS PATIENT & PHARMA MEDICATION MANAGEMENT NEEDS
CONNECTIVITY
Neil Williams
Phillips Medisize
LOW-COST CONNECTIVITY MEETS PATIENT & PHARMA MEDICATION MANAGEMENT NEEDS
Neil Williams describes the potential connected drug delivery systems hold to address serious challenges in healthcare, including poor adherence, and also deliver substantial value, and outlines the company’s highly scalable enterprise platform, the Connected Health Platform.
ADHERENCE TO SELF-INJECTION REGIMENS CAN BE ENHANCED BY CONNECTED DEVICES
CONNECTIVITY
Craig Baker
Noble
ADHERENCE TO SELF-INJECTION REGIMENS CAN BE ENHANCED BY CONNECTED DEVICES
 Craig Baker looks at the factors contributing to non-adherence and explores how connected devices can help patients follow their self-injection regimens.
ADDING CONNECTIVITY TO DRUG DELIVERY DEVICES
CONNECTIVITY
Tsachi Shaked
ADDING CONNECTIVITY TO DRUG DELIVERY DEVICES
Tsachi Shaked explores how – as the trend towards moving healthcare from the hospital to the home continues – connectivity in drug delivery devices may be changing from being the exception to the rule.
A PATIENT CENTRIC AND PHARMA COMPANY CENTRIC PREFILLED WEARABLE BOLUS INJECTOR
WEARABLES
Jesper Roested
A PATIENT CENTRIC AND PHARMA COMPANY CENTRIC PREFILLED WEARABLE BOLUS INJECTOR
Jesper Roested explains why the pharma/biotech drug development process often means device selection occurs after Phase II despite the advantages of earlier selection being well understood, and how this then precludes the selection of novel primary packaging and delivery systems.
COMPANY SHOWCASE: Cristal Therapeutics
INJECTION
Dr Cristianne Rijcken
COMPANY SHOWCASE: Cristal Therapeutics
Over the past year, Cristal Therapeutics has transitioned from a research-stage start-up to a fully fledged, clinical-stage business with a promising pipeline of proprietary drug candidates. This diverse pipeline together with the proprietary nanoparticle platform, CriPec®, presents a broad range of promising late- and early-stage partnering opportunities for companies active in the oncology space.
A NEW MULTI-COMPENDIA MODIFIED BETA-CYCLODEXTRIN, KLEPTOSE<sup>®</sup> HPB-LB PARENTERAL GRADE
INJECTION
Dr Elham Blouet
Roquette
A NEW MULTI-COMPENDIA MODIFIED BETA-CYCLODEXTRIN, KLEPTOSE® HPB-LB PARENTERAL GRADE
Elham Blouet introduces the latest addition to the company’s range of beta-cyclodextrins, and outlines the benefits it brings.
TECHNOLOGY SHOWCASE: Credence MedSystems Multi-Site™ Injection System
INJECTION
John Merhige
Credence MedSystems
TECHNOLOGY SHOWCASE: Credence MedSystems Multi-Site™ Injection System
Credence MedSystems introduces the Multi-Site™ Injection System – a product that addresses specific needs in the high-growth dermal filler market.
SELECTING THE RIGHT PRIMARY CONTAINER FOR INJECTABLES IN ACUTE CARE
INJECTION
Alfred Harvey
BD (Becton Dickinson & Company)
SELECTING THE RIGHT PRIMARY CONTAINER FOR INJECTABLES IN ACUTE CARE
Alfred Harvey explains why it’s important to select the right primary container presentation – and what can happen if you get it wrong.
ALTERING PATIENT TREATMENT: HOW SC DELIVERY CAN HELP PATIENTS MANAGE CHRONIC CONDITIONS
WEARABLES
Victoria Morgan
West Pharmaceutical Services
ALTERING PATIENT TREATMENT: HOW SC DELIVERY CAN HELP PATIENTS MANAGE CHRONIC CONDITIONS
Victoria Morgan looks at the benefits of combining an active pharmaceutical product with a novel subcutaneous delivery device, and highlights some of the partnerships West has with biopharmaceutical and other companies, which have led to market launches of products incorporating its on-body delivery system.
TRAINING DEVICES INCREASE PATIENT ENGAGEMENT AND ADHERENCE – CREATING BETTER OUTCOMES
INJECTION
Erin Miller
Noble
TRAINING DEVICES INCREASE PATIENT ENGAGEMENT AND ADHERENCE – CREATING BETTER OUTCOMES
Erin Miller outlines a study looking at how patients interact with training resources during the first 14 days of a new treatment – and how training devices can help increase confidence, adherence and, ultimately, overall outcomes for the millions of patients who manage their diseases through self-injection.
MULTILAYER PLASTIC VIALS & SYRINGES FOR BIOLOGICS
INJECTION
Takuya Minezaki
Mitsubishi Gas Chemical
MULTILAYER PLASTIC VIALS & SYRINGES FOR BIOLOGICS
Dr Takuya Minezaki and Tomohiro Suzuki, provide an overview of the company’s OXYCAPT™ Vials and Syringes, explaining how their multi-layered polymer material delivers the advantages of both COP and glass, and is especially suitable for biotherapeutics.
PRODUCT SHOWCASE: Zwickroell Autoinjector Testing Platform
INJECTION
Wolfgang Moersch
ZwickRoell
PRODUCT SHOWCASE: Zwickroell Autoinjector Testing Platform
ZwickRoell introduces RoboTest, its automated autoinjector testing platform, which works together with the AutoEdition 3 automation software ad testXpert III testing software.
PATIENT TOLERABILITY WITH HIGH-VISCOSITY, LARGE-VOLUME SUBCUTANEOUS INFUSIONS
EXPERT VIEW
Jennifer Estep
PATIENT TOLERABILITY WITH HIGH-VISCOSITY, LARGE-VOLUME SUBCUTANEOUS INFUSIONS
Jennifer King and Matthew J Huddleston discuss the advantages of subcutaneous drug delivery and how these have yet to be fully harnessed in currently marketed therapeutics.
NEXT-LEVEL FUTURE MANUFACTURING FOR MEDICAL TECHNOLOGY
INJECTION
Berthold Schopferer
NEXT-LEVEL FUTURE MANUFACTURING FOR MEDICAL TECHNOLOGY
Berthold Schopferer explains the lengths the production equipment company goes to in its efforts to ensure the customer is always king.
Top